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Abstract
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not so well understood. However, lifestyle risk factors for poor physical health are the same risk factors
for mental illness, including poor diet. This is reflected by the high level of poor physical health in people
with mental illness. Mediterranean, whole food diets have been associated with reduced risk for chronic
disease, but very little research has investigated their mental health benefits. We provide a model for the
pathways by which food components provided by a Mediterranean-style diet can facilitate healthy brain
function. We then review evidence for the role of selected nutrients/food components — antioxidants,
omega-3 fatty acids and B vitamins — in the brain and, hence, modulation of cognitive function and
mental health. Converging evidence indicates multiple pathways by which these nutrients can assist in
brain function, drawing from studies investigating them in isolation. There is very little work done on
synergistic actions of nutrients and whole diets, highlighting a need for human intervention studies
investigating benefits of Mediterranean-style diets for mental, as well as cardiometabolic health.
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ABSTRACT
Dietary risk factors for cardiometabolic health are generally well recognised; for mental
health they are not so well understood. However lifestyle risk factors for poor physical health
are the same risk factors for mental illness, including poor diet. This is reflected by the high
level of poor physical health in people with mental illness. Mediterranean, whole food diets
have been associated with reduced risk for chronic disease but very little research has
investigated their mental health benefits. We provide a model for the pathways by which food
components provided by a Mediterranean-style diet can facilitate healthy brain function. We
then review evidence for the role of selected nutrients/food components - antioxidants,
omega-3 fatty acids and B vitamins - in the brain and hence modulation of cognitive function
and mental health. Converging evidence indicates multiple pathways by which these nutrients
can assist in brain function, drawing from studies investigating them in isolation. There is
very little work done on synergistic actions of nutrients and whole diets, highlighting a need
for human intervention studies investigating benefits of Mediterranean-style diets for mental,
as well as cardiometabolic health.

Key words: Mediterranean diet, cognition, mental health, antioxidants, polyphenols, omega-3
fatty acids, vitamin B6, vitamin B12, folate, homocysteine
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Dietary risk factors for physical illness are also associated with increased risk of
mental illness, a growing international priority. A World Health Organisation survey
estimated that between one in four to one in six people in most countries, and nearly half of
Americans, will meet the criteria for a mental disorder during their lifetime, including anxiety
disorders, mood disorders, impulse control disorders and substance abuse disorders [1]. The
prevalence of accelerated cognitive decline and dementia is increasing at an alarming rate
worldwide, with an estimated 4-6 million new cases of dementia every year [2]. These
cognitive and mental health problems therefore carry a significant burden of disease across
the lifespan.
There is widespread concern regarding the effects of modern, typically Western
dietary patterns, i.e. consumption of high energy food with little nutritional value and
inadequate intake of foods containing essential nutrients, on physical health and obesity.
Traditional Mediterranean-style diets, characterised by high consumption of vegetables, fruit,
legumes, olive oil, fish, cereals, nuts and seeds, moderate consumption of red wine, and low
intakes of processed food, red meat, dairy products and vegetable oils, have been associated
with improved cardiovascular health and decreased mortality [3], and protective benefits for
cancer [4], obesity and diabetes [5]. These findings have largely been supported by a limited
number of intervention trials [6-10].
However relatively little attention has been given to the implications of these poor
dietary patterns for society’s burgeoning mental health problems, which is surprising given
the brain’s requirements for essential nutrients from food for its structure and function [1114] – although lifestyle approaches to mental illness are receiving more attention recently
[15-21]. Some correlational and longitudinal population studies have suggested that healthy
dietary patterns are associated with better mental health [16, 22-27] and reduced risk of
cognitive impairment [4, 28-31]. There are very limited dietary interventions investigating
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mental health outcomes: only 2 studies were identified in a relatively recent systematic
review [6] and some in process [16] with an important call for more research in this area [20,
21, 32].
Nutritional supplement interventions have shown some promise in improving
cognitive function and mental health. Randomised controlled trials have shown improved
cognition in students with multi-micronutrient supplementation [33], likely to be particularly
evident in children who are underperforming/living in low socio-economic areas [34];
substantially reduced violent behaviour in juveniles with mental health issues following
micronutrient supplementation [35]; and 26-35% reduction in reprimands for violent
behaviour in young adult offenders with micronutrient and omega-3 polyunsaturated fatty
acid (n-3 PUFA) supplementation [36, 37]. Some nutrients important for brain function, that
are also associated with a healthy Mediterranean-style diet, include antioxidants (e.g.
vitamins A, C and E; polyphenols), omega-3 polyunsaturated fatty acids (n-3 PUFAs), B
vitamins, monounsaturated fatty acids (MUFAs), vitamin D, and minerals including iodine,
magnesium, zinc, selenium, potassium and iron. Individually many of these nutrients have, to
varying degrees, been investigated for their association with and/or impact on cognition
and/or mental health [38]. In particular, while iodine has been identified particularly for its
critical role in early brain development [39-41], antioxidants [42-44] B vitamins [45-47] and
n-3 PUFA [48] have received notable attention in this area relative to other nutrients.
Although still somewhat on the outskirts of mainstream thinking, increasingly
researchers are highlighting links between nutrients and mental health [17, 38, 49-51], and
understanding of the underlying complex molecular mechanisms is advancing [52-54].
Importantly, although nutrients are critical for the developing brain, recent research on brain
neurogenesis and plasticity confirms that good nutrition is important for optimal brain
function throughout the lifecycle [52]. Increasing focus is also now placed by researchers on
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brain-nutrition-gene interactions with suggestions that not only does genetic variation
determine our individual response to nutrients but that nutrition and other lifestyle factors can
influence gene expression and modulate brain function [53]. The purpose of this paper is to
give a broad overview of research on food-derived antioxidant compounds – which
predominate in a plant-based diet – and then a more detailed review of biochemical pathways
of n-3 PUFA and B vitamins in brain function, and how these nutrients might therefore
modulate mental health and cognition. Figure 1 gives a diagrammatic overview of the model
that informs this.

Figure 1: Overview of links between Mediterranean-style diet and healthy brain function via plant compounds
and nutrients

ANTIOXIDANTS
Oxidation and the brain
Oxygen is required for the body’s metabolic activities which sustain life; however this
process, as well as exogenous damage from environmental sources such as exposure to air
pollutants, tobacco smoke, drugs, pesticides and radiation, produces free radicals (e.g.,
superoxide, nitric oxide and hydroxyl radicals) and other reactive oxygen species (ROS; e.g.,
5

hydrogen peroxide, peroxynitrite, and hypochlorous acid) [55, 56]. These are unstable
molecules with one or more unpaired electrons that, when they exceed the body’s oxidant
stress defense mechanisms, can start rampant chain reactions: acquiring electrons from other
vulnerable molecules leaving those molecules unpaired so they need to find another electron
in turn etc. These highly toxic molecules can result in impaired cellular lipid membranes and
cell functions, and oxidized proteins, DNA, RNA and cell death – contributing to a range of
chronic degenerative diseases, including cardiovascular disease, cancer, and premature aging.
The brain is especially vulnerable to oxidative damage for several reasons [57-60]. For
example, being lipid-rich and metabolically active with modest antioxidant defense
mechanisms, it is particularly vulnerable to lipid peroxidation which decreases cell membrane
fluidity and can damage membrane proteins, render receptors, enzymes and ion channels
inactive, and ultimately break down membrane integrity. Other factors contributing to
oxidation in brain include reaction of neurotransmitters dopamine, serotonin and
norepinephrine with oxygen, with a resulting depletion in levels of glutathione, the most
abundant endogenous antioxidant in the brain; and release of iron and copper ions following
damage to brain in forms that catalyse free radical activity [58]. Drawing from
multidimensional evidence in schizophrenia, cognitive decline, bipolar disorder and
depression, anxiety disorders, substance abuse, autism and attention-deficit/hyperactivity
disorder (ADHD), it has been proposed that pathogenic pathways created by oxidative stress
in the brain may comprise a common underlying pathology that contributes to a range of
psychiatric disorders [61]. There is an increasing body of evidence to support the role of
oxidative stress, together with inflammatory processes, in cognitive impairment,
neurodegeneration and psychiatric disorders [60, 62].
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Nutrients as antioxidants
Antioxidants can prevent, inhibit or repair damage caused by oxidative stress [63, 64]
(Figure 2). Non-enzymatic antioxidants include nutrients, which each have unique structures
and related antioxidant functions [56]. Collectively antioxidants act in a variety of ways,
including suppressing the formation of ROS, reducing hydroperoxides, sequestering metal
ions, scavenging free radicals, stimulating the activity of antioxidant enzymes, or repairing
oxidative damage [56]. Enzymes that prevent damage from ROS require dietary minerals
selenium, copper, manganese and zinc as cofactors, as well as amino acids for their synthesis
[65]. Vitamins A, C and E – of which fruit and vegetables are rich sources – are potent
dietary antioxidants that can prevent cytotoxicity resulting from free radicals, act as direct
scavengers of ROS and upregulate antioxidant enzyme activity. Vitamin C acts by becoming
oxidized itself (providing an electron), thereby stopping the chain reaction, and appears to be
particularly important for brain defenses as reflected by its high levels in cerebrospinal fluid
and brain relative to plasma [58]. From the vitamin E group of tocopherols and tocotrienols,
alpha-tocopherol appears to be the main form present in brain and its deprivation causes
neurological damage [58]. Vitamins E and A prevent lipid peroxidation which is critical for
the preservation of cellular membranes. Vitamin C works synergistically with vitamin E by
restoring its radical scavenging activity [66]. A combination of the antioxidants vitamin C,
vitamin E and alpha-lipoic acid was shown to improve flow-mediated dilation in elderly
people, presumably by reducing plasma free radicals and restoring endothelial function [67].
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Figure 2: Antioxidant and brain overview. ROS=reactive oxygen species

n-3 PUFAs inhibit production of free radicals and have been shown to reduce
oxidative stress created by traumatic brain injury in a rat model [68]; vitamins B 6 , B 12 and
folate prevent oxidation via their role in the metabolism of homocysteine which can cause
oxidative stress in endothelial cells [55] (see sections on n-3 PUFAs and B vitamins).
Glutathione and peroxiredoxin/thioredoxin are the body’s major intracellular antioxidants
thereby influencing every system in the body [58, 69]. Although these are not essential
nutrients, the enzymes glutathione peroxidase and thioredoxin reductase require selenium as a
cofactor, which works synergistically with vitamin E [65], and glutathione has close
relationships with intracellular amino acids, especially those that contain sulfur. Accordingly,
a range of dietary amino acids has been shown to enhance glutathione production: cysteine,
glutamic acid, glycine, serine, arginine and methionine [69].

8

Polyphenols as antioxidants
Plant-derived food, including fruit, vegetables, legumes, grains [70], nuts [71], red
wine [72], tea [73], olive oil [74], herbs and spices [75], also contains thousands of nonnutrient compounds called phytochemicals: phenolic and polyphenolic compounds with
antioxidant properties. They all have at least one aromatic ring structure with one or more
hydroxyl groups; and can then be classified via their chemical structure into at least ten
different classes. The largest is the group of more than 4,000 flavonoids (with the following
sub-groups: flavonols, flavones, flavonones, chalcones and anthocyanidins)[73, 76] which act
primarily by scavenging ROS as well as metal chelation, breaking chains, preventing ROS
formation and protecting ascorbic acid [77]. Importantly, various flavonoids can traverse the
blood-brain barrier [58, 77], and there is some evidence for neuroprotective benefits via
various mechanisms including direct scavenging of free radicals and assisting antioxidant
defense mechanisms within cells via modulation of signaling cascades [77]. Other
polyphenols include isothiocyanates [64]; stilbenes (e.g. resveratrol in red grape skin) [78,
79]; phenolic acids [79, 80]; lignans (in linseed) [79]; beta carotene and other carotenoids
including lycopene and lutein [55, 81]. Associations between fruit and vegetable
consumption and lower risk of chronic disease have been attributed largely to antioxidant
properties of phytochemicals [81-83], although they are thought to have other biological
functions that are not yet fully understood via modulating the activity of numerous enzymes
and cell receptors [75]. Recent studies have focused on Nrf2 [nuclear factor erythroid 2 p45
(NF-E2)-related factor 2], a transcription factor that is activated by phytochemicals and plays
a key role in the expression of genes responsible for antioxidants such as glutathione and
antioxidant and detoxification enzymes [64, 84]. In support, a most recent paper reported
increased neuronal superoxide dismutase and glutathione peroxidase activities via activation
of the Nrf2 pathway with curcumin supplementation in a neurodegenerative rat model [85].
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It should be noted that, although research has focused predominantly on antioxidant
properties of dietary polyphenols, there is evidence that their beneficial effects in brain
extend to decreasing inflammation and numerous roles in neurological signaling pathways,
e.g. via their role in expression of genes that encode antioxidant enzymes, neurotrophic
factors and cytoprotective proteins – all contributing to neuronal stress adaptation and thereby
decreasing neurodegeneration [77, 86]. Studies with rodents have reported significant
reductions in a range of indices of age-related motor and cognitive decline following
blueberry, blackberry, cranberry and strawberry extracts or walnut supplementation [19].
Although oxidative stress markers, measured by DCF fluorescence and glutathione levels in
the brain, were reduced, other mechanisms of action were also proposed including improved
neural signaling, buffering against excess calcium to prevent lowering of calcium
homeostasis and reduction of stress signals (refer to Joseph et al. for a review [19]).
Interestingly, hormetic-enhanced stress reduction has been proposed as a common pathway
for the attenuation of age-related behavioural deficits observed via caloric restriction as well
as polyphenol-rich diets [19]. Finally, Jenner’s group proposes that primary systemic health
benefits of flavonoids, as well as tocopherols and tocotrienols, may be attributed to a role in
maintaining gut health. This is indicated by their discovery that, although bioavailability of
flavonoids is low, there is a reliable breakdown into simple phenolic structures in the colon
[87, 88]. This may contribute to brain function via the brain-gut axis [89].
Research linking antioxidants and cognition/mental health
Scapagnini et al [60] provide an overview of converging evidence for the role of
various antioxidant nutrients or cofactors and compounds, such as selenium, zinc, vitamins C,
E and A, carotenoids, and polyphenols - especially curcumin and green tea - in mood,
cognition and mental health, prevention of oxidative damage to cellular membranes or DNA
in the CNS or improved serotonin, dopamine, and glutathione levels that appear to be
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modulated via markers of antioxidant activity. Human studies in mental health include a
recently published prospective study in Italy that reported associations between low
circulating carotenoids and depressive symptoms both at baseline and prospectively over 6
years, controlling for confounders [90], and reduced risk of Alzheimer disease with high
intake of vitamins C and E after multiple adjustments in the Rotterdam study [91]. Bouayed
reviewed antioxidant properties of polyphenols and their pharmacological effects on the
CNS. Coupled with evidence for ameliorating anxiety and depression in rat models, research
investigating their effects on anxiety and depression in humans is warranted [92].
A randomised controlled trial with vitamin C reported improved mood in healthy
participants [93] and a recent systematic review of studies of polyphenols and cognitive
outcomes reported cognitive benefits with polyphenol consumption [94]. A randomised
controlled trial of Pycnogenol (containing phenolic acids, catechin, taxifolin and
procyanidins) supplementation reported improved symptoms in children with ADHD [95],
accompanied by increased glutathione levels and total antioxidant status [96]. In adults with
ADHD a crossover trial comparing Pycnogenol, methylphenidate and placebo over 3 weeks
did not show improved symptoms in the treatment groups compared with placebo which may
be attributed to methodological limitations with dosage, duration and crossover effects [97].
People with schizophrenia who were given vitamins C and E along with n-3 PUFAs EPA and
DHA for four months showed reduced psychopathology on a variety of measures [98].
Although biological plausibility is strong for antioxidant treatment of cognitive and mental
health, more human studies are needed.

OMEGA-3 POLYUNSATURATED FATTY ACIDS
Long chain (LC) PUFA arachidonic acid (AA, 20:4n-6) and docosahexaenoic acid
(DHA, 22:6n-3) are highly concentrated in the brain and are vital fatty acids for neurological
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development [99-102]. Furthermore there is a growing body of evidence for their role in
mental health across the lifespan [48, 103]. Their parent fatty acids linoleic acid (LA, 18:2n6) and alpha-linolenic acid (ALA, 18:3n-3), respectively, are the two essential fatty acids we
must obtain from our diets, because humans do not have the enzymes required for their
synthesis. A diet rich in vegetables, nuts and seeds will provide abundant ALA. Humans do
have the necessary enzymes to elongate and desaturate LA and ALA to AA and DHA
respectively, but the amount of DHA that is synthesised from ALA is limiting [104-106].
Although we do not know whether this translates to conversion rates in neural tissue [104],
researchers generally suggest that preformed n-3 LC PUFA is the ideal dietary source. Indeed
it is argued that DHA should be considered as a semi-essential nutrient [107, 108]; that is, a
nutrient that we can synthesise but not in adequate amounts for optimal health and therefore
we should consume it directly from our diets – predominantly via fatty fish intake.
Current dietary intake of fatty acids [101, 109-113] suggest that we do not have any
deficiency in n-6 PUFA intakes and there is an argument that we are probably consuming too
much LA [114, 115], due to high intakes of vegetable oils and processed food. We are
certainly not consuming enough LC n-3 PUFA for optimal health, especially DHA [110].
There are major detrimental effects when AA and DHA are deficient in the diet or there is an
imbalance between these two fatty acids [116]. This part of the review will focus on known
mechanisms for the contribution of LC n-3 PUFA, especially DHA, to optimal brain function,
increased neuronal cell growth and survival, and protection from injury. Diagram 1 shows a
neuron, associated glial cells, the blood supply and the blood brain barrier. We have
identified six key mechanisms by which LC n-3 PUFA affect brain health and each of these
are shown by detailed diagrams stemming from Diagram 1. Please note that a great deal of
the mechanistic evidence is derived from animal studies and in vitro evidence such as cell
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culture work. However due reference to human evidence will also be incorporated where
applicable.

Diagram 1. Neuron associated glial cells

LC PUFA as structural components of the cell membrane of the brain
AA and DHA are major structural components of brain cells [117]. The essential fatty
acids, LA and ALA, as well as eicosapentaenoic acid (EPA), are only found in trace amounts
in brain phospholipids and EPA (precursor to DHA) is found mainly in phosphatidylinositol
(PI) [118]. However, an important role of EPA in the brain may be related to actions of
eicosanoids which is explained later. Phospholipid molecules contain hydrophic tails
(repelled by water; therefore aggregate) and a hydrophilic head (attracted to water), enabling
them to form lipid bilayers. The different phospholipid structures include phosphatidic acid
(PA), phosphatidylethanolamine (PE), phosphatidylcholine (lecithin; PC), phosphatidylserine
(PS) and phosphoinositides (PI, PIP, PIP2 and PIP3). These structures enable a multitude of

13

complex chemical pathways and processes involved in cellular structure and function
including signal transduction.
Increasing brain PC, PE, PS and PI levels
In order to synthesise PC, cytidine (the major circulating pyrimide in rats) is required
as precursor of cytidine triphosphate (CTP), which together with phosphocholine can be
converted to CDP-choline, and then together with diacylglycerol (DAG) can be converted to
PC [119]. However, cytidine and CDP-choline are not readily taken up by the brain. In rats,
oral intake of CDP-choline does not increase brain levels (0.2% of administered dose ended
up in the brain versus 60% in liver) [120]. An alternative way to synthesise PC is by using
uridine, which is the major circulating pyrimide in humans and gerbils [121]. The brain is
known to be able to take up uridine [122] as there is a high-affinity nucleoside transporter
(CNT2) at the blood brain barrier (BBB) that allows the uptake of uridine but not cytidine
[123]. Humans use uridine for the synthesis of PC in the brain via the Kennedy cycle [119,
124]. Uridine is converted to uridine triphosphate (UTP) which together with phosphocholine
is subsequently converted to CDP-choline, which when combined with DAG forms PC. DHA
is used in the formation of DAG, and DHA-rich DAG is preferentially used for the synthesis
of phospholipids used for membrane synthesis [125].
CDP-DAG together with serine can form PS and CMP. Subsequently PS can be
decarboxylated to form PE and via 3 methylation steps PE can be converted to PC.
Furthermore, like PC explained above, PS and PE can be synthesised directly from serine and
choline respectively. CDP-DAG together with inositol can be converted to PI [126].
Figure 3 shows the different glycerophosphates (phospholipids) as % of dry weight
from human brain gray matter, white matter and myelin (data taken from O’Brien et al.
[117]). Generally the choline glycerophosphates (CGP) and ethanolamine glycerophosphates
(EGP) are in similar proportions across the age groups with serine glycerophosphates (SGP)
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being the lowest. Figures 4a-4c show the major fatty acids associated with the different
glycerophosphates (data taken from O’Brien et al. [127]). The greatest proportion of PUFA
(40-60%) is found in gray matter in EGP and SGP (Figures 4b and 4c), with very little in
CGP (Figure 4a). Palmitic acid differed in the 3 glycerophosphates, being the highest in CGP
and extremely low in SGP. Myelin contained the least amount of PUFA (especially in CGP
and SGP) and highest amount of oleic acid (and nervonic acid, data not shown). There was no
real effect of age, except possibly an increase in oleic acid in gray matter [127] as well as a
pronounced decrease in stearic acid and increase in DHA (55 y compared to 9 y) in SGP. The
increase in DHA in SGP could be indicative of our neural cell survival (see survival section).
Furthermore, even though CGP contains very little DHA, there is a notable increase in CGP
DHA levels in gray matter at 55 y compared to earlier years (Figure 4a). This increase could
also be due to neuronal cell survival, as plasma CGP-DHA levels are reduced in people with
Alzheimer’s disease [128] (see section on neurodegeneration).
Note that the data shown in figures 4a-c is taken from n=1 for each age group and
there is likely to be some variation, which could come from dietary intake and physiological
requirements. Currently we do not have any human data that shows the direct effect of dietary
fatty acids with the amount of fatty acids in the brain. We do know however, that dietary
EPA and DHA correlate very well with circulating EPA and DHA in plasma and erythrocytes
membranes [129]. Most other dietary fatty acids are metabolised prior to uptake into tissues
and therefore do not correlate to circulating levels, e.g. dietary LA does not correlate to tissue
levels of LA, as LA is metabolised to AA, and AA is then taken up by the tissues. Whilst
dietary EPA and DHA do correlate to circulating levels and dietary intakes affect these
levels, we do not definitively know what extent these dietary effects are in the brain. The
likely greater influences to the variation of brain fatty acids are physiological and
pathophysiological. There may be a hierarchy of fatty acid accumulation in the brain (i.e.
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DHA is preferentially in EGP and SGP in the gray matter of the brain in Figures 4b and 4c
but not in CGP as shown in Figure 4a). Therefore one can see from the graphs that this
hierarchy of where DHA is in the brain is most likely not to be highly influenced by dietary
intake but is most likely driven by physiology. Furthermore, DHA has been found to be at
sub-optimal levels in the brains of people that had Alzheimer’s disease (see
neurodegeneration), yet dietary intake of DHA does not appear to be deficient [130].
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Figure 4b: proportion of fatty acids in EGP = ethanolamine
glycerophosphates). 22:6n-3 = DHA; 22:5n-3 =
docosapentaenoic acid (n-3); 22:5n-6 = docosapentaenoic acid
(n-6); 20:4n-6 = arachidonic acid; 18:1n-9 = oleic acid; 18:00 =
stearic acid; 16:00 = palmitic acid. All male Caucasian, n=1 in
each age group.
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Figure 4a: proportion of fatty acids in CGP (= choline
glycerophosphates). 22:6n-3 = DHA; 22:5n-3 =
docosapentaenoic acid (n-3); 22:5n-6 = docosapentaenoic acid
(n-6); 20:4n-6 = arachidonic acid; 18:1n-9 = oleic acid; 18:00 =
stearic acid; 16:00 = palmitic acid. All male Caucasian, n=1 in
each age group.
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human (all male Caucasian, n=1 in each age group) gray matter,
white matter and myelin (data taken from O’Brien et al (107)). CGP
= choline glycerophosphates; EGP = ethanolamine
glycerophosphates; SGP = serine glycerophosphates.
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stearic acid; 16:00 = palmitic acid. All male Caucasian, n=1 in
each age group.
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The synthesis of phospholipids requires all the raw ingredients (or substrates) to be
present; otherwise the amount and quality of the phospholipid can be compromised. In animal
studies, gerbils fed uridine alone did not increase phospholipids (PC, PE, PS and PI). Gerbils
fed DHA alone did not increase PC levels but did increase the other phospholipid classes (PE,
PS, and PI) to some extent. However gerbils fed both uridine and DHA increased PC levels
by 28%. DHA alone increased PE by 26% and in combination with uridine by 59%. DHA
alone increased PS by 75% and in combination with uridine by 160%. DHA alone increased
PI by 29% and in combination with uridine by 100% [131]. These results suggest that the
addition of DHA amplifies the phospholipid synthesis and that there is a hierarchy of
preferred synthesis of the different phospholipids species with incorporation of DHA being
the highest in PS followed by PI, then PE and PC. The doubling of PS may have implications
for increased survival of neurons (see section on survival below).
Animal studies have been supported by cell culture studies using pheochromocytoma
neuroendocrine cells (PC12 cells). DHA is taken up by these cells and is activated by acyl
CoA synthetases [132, 133], which can now be used for the synthesis of DHA-containing
phospholipids. Given that DHA enhances phospholipid synthesis, as explained previously,
and the increased phospholipids promotes neurite outgrowth [134], then one can deduce that
DHA promotes neurite growth. Furthermore the effect of combined uridine, choline and
DHA can result in increased number of synapses and dendritic spines [134] as explained
below.
The effect of LC PUFA on neurite growth (Diagram 2)
For successful outgrowth of neurites from developing neurons, the cell first increases
its membrane surface area [135]. In order to do this, the cell requires 1) a signal which is
provided by the nerve growth factor (NGF) [136]; 2) phospholipase A2 to release the
necessary fatty acids (AA and DHA) [137]; 3) a specific target molecule for fatty acids that

17

can facilitate the necessary fusion of the plasma membrane, which has been identified as
syntaxin 3 [138]; and 4) fusion proteins, namely, soluble N-ethylmaleimidsensitive-factor
attachment protein receptor (SNARE) to facilitate fusion of membranes [139, 140]. The
ability of syntaxin 3 to partner with SNARE requires AA and DHA [138].
Therefore upon the stimulus of the NGF, PLA2 releases AA and DHA from the cell
membrane and these fatty acids bind to syntaxin 3, a plasma membrane bound protein, and
with the help of SNARE proteins, they promote fusion of the membrane phospholipid bilayer
thus enabling neurite outgrowth. In the cell culture studies by Darios et al [138], fatty acids
that can facilitate the neurite outgrowth are LA, AA, ALA, DHA, but not saturated fatty acids
or monounsaturated fatty acids. LA and ALA are the precursor fatty acids for AA and DHA
respectively [101], but are not found in appreciable amounts in the brain. Thus neurite
outgrowth is reliant on AA and DHA being present in the brain.

Diagram 2. The effect of DHA on neurite growth

However another study using gerbils showed that EPA and DHA, but not AA,
increased brain phospholipids as well as synaptic proteins [121]. This study also showed that
the combination of uridine (food sources include tomato and broccoli), choline (food sources
include egg, cod fish, wheat germ, cauliflower, spinach, quinoa) and DHA or EPA resulted in
a further increase of phospholipids and synaptic protein levels than just the fatty acids (DHA
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or EPA) alone. The cell culture studies described by Darios et al [138] above suggest that AA
is as effective as DHA to promote neurite outgrowth. In contrast, this in vivo study by Cansev
and Wurtnam [121] showed AA not to be effective. The limitations of cell culture studies is
that it is an isolated environment which is usually tightly controlled, whilst in vivo studies
using animal models (e.g. gerbils) is a closer representation of what will occur in the whole
body in a complex system. The reason for the difference between AA not being effective in
vivo, but is effective in cell culture studies is unknown but as suggested by Cansev and
Wurtman [121] could be due to: different affinities in uptake, different affinities for the
enzymes involved in DAG and phospholipid formation, differential activation of genes
encoding proteins needed for membrane synthesis [141], different rates of deacylation, or
different biochemical pathways other than via the Kennedy cycle [142], or the different halflives where blood DHA and EPA are much higher than AA [143, 144].
DHA has also been shown to stimulate neurogenesis in rat embryo neural stem cells
in vitro as well as increasing the number of newborn neurons in the granule cell layer of the
dentate gyrus in adult rats in vivo [145]. Therefore DHA is important not only in the
formation of new neuronal cells, but increasing the number of neurones in the adult brain.
Furthermore, uridine, choline and DHA have been shown to increase the levels of various
proteins required for the synthesis of synapses. Gerbils fed a combination of uridine, choline
and DHA resulted in increased levels of the vesicular protein synapsin-1 (41%), post-synaptic
protein PSD-95 (38%) and neurite neurofibrillar proteins NF-M (48%) and NF-F (102%)
suggesting an increase in the number of synapses [134]. Increased dendritic spines and
number of synapses was also achieved following oral supplementation with DHA alone and
particularly in combination with uridine [131].
The evidence to date suggests that we need a combination of molecules (uridine,
choline, AA, DHA) for neurite outgrowth, synthesis of synaptic membranes and dendritic
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spines. It is pleasing to note that mother nature has taken care of this, as breast milk contains
uridine, choline, AA and DHA to promote normal growth [146, 147].

Diagram 3. Phospholipid bilayer DHA

LC PUFA and membrane fluidity (Diagram 3)
Cell membranes are made up of a phospholipid bilayer, with cholesterol and proteins
embedded in it (Diagram 3). The spatial arrangements of these phospholipids are dependent
on the fatty acyl chains associated with the phospholipids. The usual combination of fatty
acids to phospholipids is one saturated fatty acid and one unsaturated fatty acid per
phospholipid molecule irrespective of the polar head group [148]. In the brain, the most
abundant saturated fatty acids are palmitic (16:0) and stearic (18:0) acids and the most
abundant unsaturated fatty acids are DHA, arachidonic acid (AA, 20:4n-6) and oleic acid
(18:1n-9) [117, 148] (see Figures 3 and 4 above). The spatial arrangements of these
phospholipids are dependent on the fatty acyl chains associated with the phospholipids. For
example, the spatial arrangement used by a saturated fatty acid with no double bonds is much
less than that of DHA (22:6n-3, with 6 double bonds) [101]. The activity of membrane bound
enzymes, like the sodium potassium ATPase are influenced by the fluidity gradient of the
membrane [149]. Cell membrane fluidity, or flexibility of movement through a lipid bilayer,
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is influenced by highly unsaturated fatty acids like DHA, i.e. the higher the DHA content, the
greater the fluidity/flexibility. A good example of scientific evidence that supports this
membrane fluidity theory is rhodopsin. Usually when light hits rhodopsin in the eye,
elongation of rhodopsin occurs which is necessary for good vision [150] and when DHA is
replaced with docosapentanoic acid (22:5n-6) in the eye conformational changes occur that
affect the rhodopsin photocycle [151]. Human studies support this in that supplementation
with DHA in infants results in increased visual acuity, especially in girl infants [152].
LC PUFA and neurotransmitters (Diagram 4)
The effect of DHA increasing synapses and membrane fluidity such that membrane
proteins have improved function also relates to neurotransmitters (diagram 4). It is well
known that neurotransmitters are synthesised from specific amino acid precursors; namely,
acetylcholine (precursor choline), serotonin (precursor tryptophan), nor-epinephrine and
dopamine (precursor tyrosine) [153]. Therefore brain levels of choline, tryptophan and
tyrosine will affect the respective neurotransmitter levels. When neurotransmitters are
released from the synapse, they bind to specific receptors; namely, serotonin binds to 5-HT1
receptor, nor-epinephrine binds to a’-2 beta receptor, dopamine binds to the D1 and D2
receptor (Diagram 4). Taking dopamine as an example, once dopamine binds to its receptor,
this increases protein kinase A activity, which in turn phosphorylates ion channels and hence
allows them to open up and therefore allowing the signal to be transmitted. Experimental
evidence shows that when the LC n-3 PUFA is low, protein kinase A activity is reduced
which results in reduced phosphorylation of ion channels resulting in reduction of ion
channels opening up [101, 154]. This means that in conditions where LC n-3 PUFA is low,
more dopamine is needed to depolarise the cell. Therefore for effective neurotransmission we
need LC n-3 PUFA to be present in cell membranes of the brain. In support, a series of rat
studies identified that profound n-3 PUFA deficiency impacts on dopaminergic and
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serotonergic systems, and that a reversal diet can enable some recovery of dopamine and
serotonin levels [155]. A further study identified increased levels of brain derived
neurotrophic factor (BDNF) – which is known to facilitate synaptic transmission – after
dietary DHA supplementation in rats following a traumatic brain injury which had reduced
BDNF levels [68]. In this study, which also showed decreased oxidative stress as mentioned
in the earlier section on antioxidants, impaired learning following the brain injury was
attenuated with DHA supplementation.

Diagram 4. DHA and neurotransmitters

LC PUFAs and the endothelium: eicosanoids and blood-brain barrier (Diagram 5)
Prior to describing what goes on in the brain, the effect of LC PUFA and eicosanoid
production should be explained. A person’s cell membrane fatty acid composition reflects
their dietary fatty acid intakes. The Inuit’s blood fatty acid profile showed very high levels of
the LC n-3 PUFA, EPA and DHA and low levels of AA because they consumed a diet high
in whales and seals which are rich in LC n-3 PUFA. These LC n-3 PUFA get incorporated
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into cells throughout the body and displace LC n-6 PUFA [156]. Documented by early
explorers, Inuit had a propensity for spontaneous frequent nose bleeds and when wounded on
the battle field, they lay there bleeding for quite a long time before their blood would clot
[157]. This was subsequently explained by the eicosanoids formed from the fatty acids
released from the endothelial cells lining the blood vessels. The eicosanoids produced from
the LC n-3 PUFA are prostaglandins and leukotrienes of the 3- and 5-series, which inhibit the
prostaglandins and leukotrienes of the 2- and 4-series produced from AA and result in
reduced blood clotting therefore increased blood flow [158]. Eicosanoids from the 3- and 5series also have anti-inflammatory and vasodilatory properties [159, 160].

Diagram 5. Eicosanoids and blood‐brain barrier

A recent study by Ajmone-Cat et al [161] showed that DHA inhibited the synthesis of
inflammatory products, including IL-6, TNF-alpha, in activated microglia in cell culture
studies. This effect of DHA could be due to resolvins and neuroprotectins produced from
DHA, although more research is warranted, and could have implications for reducing the
inflammatory process that is associated with neurodegenerative diseases (discussed later).
In addition to anti-inflammatory and vasodilatory properties, LC n-3 PUFA have an
effect on glucose transport and uptake by the brain – via endothelial cells of the blood brain
23

barrier. It is well known that the brain utilises glucose as its energy source [153] and can use
ketone bodies during periods of starvation [162], but not exclusively. Studies based in rats
have shown that dietary DHA deficiency resulted in 30-50% reduction in brain membrane
DHA levels in phospholipids and this corresponded to a 30% reduction in glucose uptake
across the blood brain barrier [163]. It was subsequently shown that glucose transporter in
astrocytes (GLUT-1 45kDalton isoform) was reduced by approximately 30% but the neuronal
glucose transporter (GLUT3) was unaffected [164]. This reduced GLUT1 in astrocytes is due
to reduced post-transcription of the glucose transport protein itself, as mRNA for GLUT1 was
not affected [164]. Therefore a deficiency may result in reduced glucose supply to the brain
(as shown in rat studies), but it is not known if increased levels of DHA would result in
increased glucose supply and uptake by the brain. However, DHA appears to be concentrated
in tissues that utilise a lot of energy, such as the brain and retina. Brenna et al [165] took data
from a study in monkeys where they measured local cerebral metabolic rate for glucose [166]
and plotted that against their own DHA levels with a resulting correlation of r2 = 0.68,
p=0.0003 [165]. These properties of LC n-3 PUFA are consistent with the hypothesis that
they play a role in endothelial function in the brain which may improve blood flow and
blood-brain barrier integrity [167], as well as reducing inflammation in the brain. In support,
Jackson et al reported a direct effect of a high-DHA supplement on cerebral blood flow in the
cerebral cortex of healthy adults compared with placebo [168]. Not only is glucose – and
glucose delivery – required for ongoing brain function but reduced cerebral blood flow [167]
and inflammation [169] have both been associated with mental illness. Insulin has also been
shown to cross the blood-brain barrier. Recent research has demonstrated in a rat model that
fructose intake coupled with DHA deficiency led to insulin resistance in the brain, as well as
memory impairment; whereas a DHA-enriched diet counteracted these effects via improved
synaptic plasticity and reduced glucose-induced peroxidation of the endothelium [170].
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Neuronal survival (PS-DHA) (Diagram 6)
Neuronal survival appears to be linked to the amount of PS-DHA in the brain. Human
brains will do their utmost to ensure that the levels of PS-DHA are maintained. In situations
where DHA deficiency occurs and DHA supply in the brain is limited, DPAn-6 is substituted
for DHA (similar to what occurs in the eye, as explained above) in PS in the brain [171] and
may play a role in further PS-DHA depletion [172]; this appears to be a survival mechanism.
At least in vitro cell culture studies, supplementation with DHA and DPAn-6 (but not oleic
acid) increases PS synthesis [173, 174], with DHA being more effective [172].
Alcohol consumption impairs the biosynthesis of PS [175] and therefore contributes
to the loss of PS from the brain. PS-DHA is extremely important for neuronal cell survival
[172]. Given that neuronal cells do not regenerate very well, it is important that they have a
mechanism in place that ensures their survival. One such mechanism is maintaining the high
levels of PS via DHA enrichment of PS in their membranes [172]. As explained above, a
combination of uridine, choline and DHA more than doubles PS-DHA in gerbils brains [131].
Therefore DHA encourages survival of brain cells and in order to maintain a healthy brain
that is able to survive, we need to ensure that there are adequate amounts of DHA and that the
brain can synthesise PS-DHA and also prevent its depletion (i.e. no alcohol intake).
Another survival mechanism is via neuroprotectin D1 (NPD1). NDP1 (10, 17Sdocosatriene) is synthesised from DHA [176] due to an insult like ischemia. Ischemia induces
a cascade of events where there is a rapid release of fatty acids (AA and DHA) by
phospholipase A2, which can be converted to a variety of oxygenated metabolites (see
section on neurodegenerative diseases). DHA is converted by the enzyme 15-LOX to 10,
17S-docotriene, known as NPD1 [176]. NPD1 is a neuroprotectin molecule because it is
known to reduce leukocyte infiltration and reduce pro-inflammatory gene expression [177].
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Other DHA metabolites are the prostaglandins F4 neuroprostanes [178]. These
neuroprostanes are increased in neurodegenerated diseases like Alzheimer’s disease [179,
180] which may be a signal for oxidative stress [172]. However, in cell culture studies,
neuroprostanes formed from DHA are potent inhibitors of NF-kb signalling and may
contribute to the anti-inflammatory actions of DHA [181]. These results are yet to be
confirmed in animal models of Alzheimer’s disease as well as human studies.
Certainly, it has been shown in animal models of Alzheimer’s disease that DHA
supplementation protects against neuronal damage [128]. This protection against neuronal
loss could be due to the maintenance of PC-DHA levels in the brain, which prevents neuronal
death, and/or via anti-inflammatory mechanisms, and/or via the promotion of neural growth.
More research is warranted to elucidate the exact mechanisms by which DHA exerts its
effects.

Diagram 6. Neural survival (PS‐DHA)
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Neurodegeneration (Diagram 7)
Ageing has been described in a recent review by Ledesma as an internal clock plus
oxidative stress [182]. The total lipids in the brain increases for the first 20 years of life,
followed by a gradual decline until 80 years of life and major changes occur after 80 years of
age resulting in a rapid decline of total lipids in the brain as a result of neurodegeneration
[182]. Figure 5 shows the levels of the different phospholipid classes (PC, PS, PE, PI) in the
whole brain (gray and white matter) for the first 40 years of life (data taken from Rouser
Yamamoto [183]).
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Figure 5: levels of the different phospholipid classes (PC, PS, PE, PI) in the whole brain (gray and white
matter) for the first 40 years of life (data taken from Rouser Yamamoto (166); extrapolated from 13 healthy male
whole brains aged 6 months to 98 years).

Ageing is associated with decreased neurotransmitter release [184] and alters
neurotransmitter signalling [185]. The aged brain has little dead neuronal cells [186] but
performance decreases with age. Oxidative stress (ROS) increases, the cell’s ability to
detoxify decreases and the cells go through adaptive processes to survive [187]. Different
degrees of severity of ROS lead to decreases in dendritic remodelling and increases in
excitotoxins, which hamper neuronal function [182].
As explained under the neurite outgrowth section, for synaptic vesicle fusion to occur,
two bilayers must merge, resulting in extreme structural changes. The ability of cell
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membrane to show curvature (i.e. DHA rich cell membrane) is a key requirement for fusion
[188]; therefore the more highly curved the more fusogenic. Synaptic membranes are rich in
AA and DHA at molar levels [189]. The ability to change the strength of a synaptic
connection (referred to as synaptic plasticity) is believed to underlie memory and learning
processes [182]. Barnes in 1979 showed a correlation between the age-associated decline in
synaptic plasticity and neuro-cognitive impairment in rats [190]. Since then it has been shown
that learning and memory deficits are related to strengthening of the synapse (memory
formation) and synapse weakening (memory loss). The thresholds for the induction of
memory formation and memory loss increase and decrease with age, respectively [191]. The
older one gets, the more forgetful one gets [192, 193], the lower the ability to remember
things and the greater the memory loss [194]. However, restoration of AA and DHA levels in
the brain could rescue the age related impairment in memory formation [195].

Diagram 7. DHA preventing cognitive decline
Ageing is associated with a decrease in NR2B (a subunit of the NMDA receptor)
which is related to a decline in learning [196]. Ageing is also related to decreases in the
AMPA receptor subunits (GluR2) in rats, which potentially could alter the calcium flux that
may be related to neurodegeneration associated with ageing [197]. GluR2 is also necessary
for the growth and maintenance of dendritic spines [198]. An ageing brain has been shown to
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have lower PUFA content. Dyall et al have shown that supplementation with EPA and DHA
in rats fully reversed the age related decrease in NR2B and GluR2 subunits and also restored
some of the phospholipid loss [199].
Phospholipase A2 can release DHA from the membrane and be converted to NDP1 by
15-LOX. NDP1 protects neuronal cells in various ways (see Diagram 7): It 1) reduces the
transcription of pro-inflammatory factors like NF-kB; 2) reduces inflammatory gene
expression (COX-2, TNF-alpha); 3) reduces pro-apoptotic proteins (Bax, Bik); 4) enhances
anti-apoptotic proteins (Bcl-2, BFl-1, Bc1-xl); 5) reduces amyloidogenesis (AB-42 peptides);
6) enhances neurotrophic cell survival (sAPPa); and 7) reduces oxidative stress, thereby
reducing apoptosis and brain cell degeneration [200]. This suggests that DHA, via NDP1 is
protective and promotes brain survival. However, during oxidative stress, DHA can be
converted to neuroprostanes (F4, D4, E4, A4, J4) which promote apoptosis and exacerbate
the oxidative damage to neuronal cells, promoting cell death [200]. Therefore in this
situation, we require antioxidants to prevent oxidative stress (refer to section on antioxidants).
It has been shown that supplementation with DHA in animals [201] and in humans
[202] can improve cognitive function, and may prevent cognitive decline in people with mild
cognitive impairment [48, 203]. Increased anxiogenic like behaviour is found in rats that have
reduced DHA [154, 204] and susceptibility to psychological stress in humans can be
improved with fish oil supplementation [205]. Certainly brain levels of choline, ethanolamine
[206] and DHA [207] have been shown to be sub-optimal in people with Alzheimer’s
disease. Furthermore, breakdown products of phospholipids (indicative of phospholipid loss
from the brain) are elevated in people with Alzheimer’s disease [206]. In an experimental
mouse model of Alzheimer’s disease, it was shown that neuronal dysfunction occurred
months before the appearance of abnormal plaques [208] and similarly in humans cognitive
decline precedes neurodegenerative diseases like Alzheimer’s disease. Hence there is
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potential for therapeutic intervention in people with mild cognitive decline to prevent the
progression to neurodegenerative diseases. Given the potential additional benefit of
supplementation with DHA, uridine and choline in combination, these clinical trials on the
potential behavioural benefits are warranted.

VITAMINS B 6 , B 12 , FOLATE AND HOMOCYSTEINE
There has been considerable interest in the role of B vitamins in cognition and brain
function, particularly vitamin B 6 , folate and vitamin B 12 , which influence homocysteine
levels throughout the body. The B vitamins represent a group of 8 water-soluble essential
nutrients: vitamins B 1 (thiamine), B 2 (riboflavin), B 3 (niacin), B 5 (pantothenic acid), B 6
(pyridoxine), B 7 (biotin), B 9 (folate/folic acid) and B 12 (cobalamin) [209]. Historically, a
severe deficiency in these vitamins was associated with profound clinical manifestations,
such as beriberi and anaemia; and neurological changes or impairment in brain function were
also commonly observed. However, what were once major public health problems in some
parts of the world have declined, replaced by evidence of a sub-clinical deficiency in B
vitamins [210]. Sources of B vitamins include a wide range of unprocessed foods such as
whole grains, lentils, beans, potatoes, bananas, chili peppers, nuts and animal products. Folate
is depleted during harvesting, storage, distribution and cooking, and in the refinement of
grains such as white rice and corn. The low bioavailability of folate in our food supply
combined with its role in fetal growth, development and prevention of neural tube defects led
to calls for folate fortification of foods [210]. In the latter half of last century, subclinical
deficiency of vitamin B 6 , folate and vitamin B 12 as a cause for physical and mental health
problems has been investigated.
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Vitamins B 6 , B 12 and Folate
Vitamin B 6 , vitamin B 12 and folate all play an important role in human metabolic
processes. There are three naturally occurring forms of vitamin B 6 : pyridoxine, pyridoxal and
pyridoxamine, and all three can also occur as phosphorylated compounds. The principal form
present in food and in the body is pyridoxal 5’-phosphate (PLP), which functions as a
carbonyl-reactive coenzyme for many reactions involved in amino acid metabolism,
including metabolism of sulphur-containing amino acids such as homocysteine, formation of
neurotransmitters epinephrine, norepinephrine, serotonin, and γ-amino butyric acid (GABA),
taurine synthesis (a conjugator of bile acids and important in eye and brain function), and
conversion of tryptophan to niacin by kynureninase [209].

Figure 6. B vitamins and homocysteine metabolism. B6, vitamin B6; B12, vitamin B12; HCY, homocysteine;
MTHF, 5-methlytetrahydrofolate; SAH, S-adenosylhomocysteine; SAM, S-adenosyl methionine; THF,
tetrahydrofolate. Adapted from Obed and Herrmann (2006).
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Folate refers to several compounds related to folic acid, including tetrahydrofolate
(THF). The most stable form of folic acid (pteroyl glutamic acid) is the primary form found
in pharmaceuticals and used in food fortification, although it is not the natural form occurring
in foods and the body. THF plays an important role in 1-carbon transfers in the body,
receiving 1-carbon radicals (also known as methyl groups) and donating them during various
biochemical reactions, and is essential for the DNA biosynthesis cycle [209, 210].
Specifically, the 5-methyl THF form together with vitamin B 12 are also required for
methionine synthase to add a methyl group to homocysteine to form S-adenosylmethionine
(SAM) (an active form of methionine and important methyl donor in all cells) and THF as
part of the methylation cycle (see Figure 6). Under normal physiological conditions this
allows rapid removal of homocysteine and the levels of homocysteine to remain relatively
low in the cell [211].
Due to the role of vitamin B 12 in methylation cycle, a deficiency in vitamin B 12 also
results in a functional folate deficiency, with folate being trapped in the methyl-5 THF form.
Although the DNA and methylation cycles both regenerate THF, folate catabolism and
excretion via the skin, urine and bile also occurs and levels must be replenished through the
diet [209]. Folate deficiency will reduce the methylation and DNA cycles. During
development, an inadequate intake of folic acid can increase the risk of improper closure of
the neural plate which goes on to form the spinal cord and cranium between 21 to 27 days
post conception. Folic acid requirements are increased during pregnancy especially during
periods of rapid fetal growth to decrease the risk of fetal neural tube defects including spina
bifida and anencephaly [210].
Vitamin B 12 , or cobalamin, is a compound only synthesised by bacteria. Its two
coenzyme forms, methylcobalamin and deoxyadenosylcobalamin, are used by the enzymes
methionine synthase and methylmalonyl-CoA mutase respectively. Methylmalonyl-CoA
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mutase plays a role in the conversion of methylmalonyl-CoA to succinyl-CoA in the
catabolism of propionate in the mitochondria. In the cytosol, methionine synthase transfers a
methyl group from 5-methyl THF form of folate to homocysteine to produce methionine
(Figure 6). Vitamin B 12 therefore also plays an important role in the use of folate and the
lowering of homocysteine levels in humans. Clinical vitamin B 12 deficiency is not usually
due to inadequate dietary intake, but rather malabsorption due to autoimmune atrophy of the
gastric mucosa, referred to as pernicious anaemia in severe cases [209]. Pernicious anemia is
known to increase with age. The deficiency causes megaloblastic anaemia similar to that seen
in folate deficiency and/or neurological dysfunction. The effects of the deficiency can be
traced back to the requirement of vitamin B 12 for conversion of folate by methionine synthase
– the methyl-folate trap – and the reduction in DNA synthesis. [210].
Homocysteine
Although elevated plasma or serum homocysteine (hyperhomocysteinemia) was once
considered no more than a marker for an impaired methylation cycle, it is now implicated in
human disease in its own right, and widely recognised as a marker for cardiovascular risk
[212, 213]. Homocysteine is a sulphur-containing amino acid produced exclusively from the
methylation cycle (Figure 6); it is not available from dietary sources [211]. The methylation
cycle also determines removal of homocysteine. Donation of a methyl group by SAM
generates S-adenosylhomocysteine (SAH). Under normal physiological conditions, when
intracellular homocysteine levels are low, SAH then is rapidly converted to homocysteine by
SAH-hydrolase within the cell. However, as intracellular homocysteine rises, the SAHhydrolase reaction shifts to favour production of SAH instead, with a resultant rise in
intracellular SAH [211]. SAH is known to be a potent inhibitor of SAM-dependent
methylation reactions. Alterations in SAM/SAH ratio will result in a decrease in activity of
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methyltranferases, with implications for methylation reactions involving DNA, proteins,
phospholipids and neurotransmitters [214].
The B vitamins play in important role in removal of homocysteine and therefore
maintenance of normal low levels. Folate and vitamin B 12 are required for the methylation of
homocysteine to methionine and remethylation and synthesis of SAM. Pyridoxal phosphate
(vitamin B 6 in its active form) is a coenzyme of cystathionine synthase and cystathionine
lysase, which are required for metabolism of homocysteine to cysteine [215]. The metabolism
of homocysteine is mostly similar throughout the body, including the brain, although some
differences occur. Although homocysteine can also be remethylated by an alternative
pathway via betaine-homocysteine methyl transferase (BHMT), it appears that this pathway
does not occur in the brain [216]. However, the action of this pathway may still affect brain
function through reduction of systemic homocysteine levels. Homocysteine can also be
transported into neurons via a specific membrane transporter [217].
Homocysteine can be easily transported in and out of cells, and measures in urine or
blood reflect intracellular homocysteine production and use. Free homocysteine represents
less than 5% of total homocysteine in plasma, as most homocysteine is present in a proteinbound form [211]. Plasma total homocysteine is a reliable marker of homocysteine levels,
with normal values in the range of 7-14 µmol/l [218]. An elevation in plasma or serum
homocysteine for an extended period of time is known as hyperhomocysteinemia [211].
Severe hyperhomocysteinemia (>100 µmol/l) has a number of genetic causes which affect
homocysteine metabolism and is associated with vascular disease, mental retardation and
seizures. Moderate (15-30 µmol/l) or intermediate (30-100µmol/l) hyperhomocysteinemia is
more commonly present in the general population. Apart from folate, vitamin B 12 or vitamin
B 6 deficiency, other determinants of moderate hyperhomocysteinemia include lifestyle
factors such as smoking, coffee and alcohol consumption, exercise and diseases such as renal
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failure, diabetes, hypothyroidism and malignancies [218]. In addition, homocysteine levels
are higher in men, increase with age and also whilst taking some medications including
methotrexate, anticonvulsants, lipid-lowering drugs and oral contraceptives [211, 218]. For
further

review

on

total

plasma

homocysteine

levels

and

determinants

of

hyperhomocysteinemia, see Refsum et al, 2004 [218].
B vitamins, homocysteine and brain function
The possible ways in which subclinical deficiency of B 6 , folate and/or B 12 could
impair brain function and increase mental health risk are multiple (Figure 7). Although there
are some proposed mechanisms which implicate B vitamins independently, most are related
to the associated increase in homocysteine.

Figure 7: Roles of B vitamins and homocysteine in one-carbon metabolism, transsulfuration pathway and brain function.
Homocysteine can be transported into neurons via a specific membrane transporter. Remethylation of homocysteine to
methionine occurs in the presence of folate and B12. Methionine is an important source of methyl groups in the brain.
Homocysteine can also be converted to cysteine (a precursor of glutathione) in the presence of B6. Homocysteine can cause
DNA damage directly or through reduction in DNA methylation, leading to synaptic dysfunction and apoptosis.
Homocysteine can lead to excitotoxicity through direct actions on glutamate receptors. Although the pathway for
remthylation of homocysteine via BHMT does not occur in the brain, it may still influence brain function through actions on
systemic homocysteine levels. Adapted from Mattson and Shea (2003).
BHMT, betaine-homocysteine methyltransferase; MS, methionine synthase; MTHFR, 5, 10-methylenetetrahydrofolate
reductase; SAH, S-adenosylhomocysteine; SAM, S-adenosylmethionine.
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B vitamins and homocysteine actions on cerebral vasculature
Elevated homocysteine is a known risk factor for cardiovascular disease [212, 213].
Considering the shared incidence of vascular disease and poor mental health, including
depression [219, 220], schizophrenia [221] and cognitive impairment [222], homocysteine
may influence brain function via vascular mechanisms. Elevated plasma total homocysteine
has been associated with white matter lesions and silent brain infarctions in older people with
and without Alzheimer’s disease, both markers of damage to cerebrovascular circulation and
risk factors for future clinically apparent stroke and cognitive decline [223, 224]. A study in
patients with subcortical vascular encephalopathy (a distinct type of vascular dementia),
cerebral large vessel disease and healthy controls found elevated plasma homocysteine in
patients with subcortical vascular encephalopathy compared with the other two groups [225].
This indicates that increased homocysteine may exert its effects by injuring small penetrating
cerebral arteries and arterioles rather than larger brain-supplying arteries.
Animal studies also point towards a possible effect of homocysteine on the
microvasculature of the brain. Feeding mice a B-vitamin-deficient diet for 10 weeks induced
hyperhomocysteinemia and damage to hippocampal microvasculature without evidence of
neurodegeneration [226]. This was accompanied by impaired special learning and memory in
the mice. The authors concluded that this damage could occur in the absence of or preceding
neurodegeneration. There is also evidence that homocysteine can increase microvascular
leakage in the brain [227], leading to vascular remodelling which could disrupt the bloodbrain barrier [228].
B vitamins and homocysteine actions on the brain
Neurotransmitters
B vitamins are required for the effective production of the monoamine
neurotransmitters serotonin, epinephrine, and dopamine. Specifically, vitamin B 12 and folate
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are required for the generation of SAM, a methyl donor in the serotonin and catecholamine
pathways. Furthermore, when intracellular homocysteine levels are elevated due to deficiency
in B vitamins, the SAH-hydrolase reaction pathways will shift to generate SAH leading to
inhibition of methylation [211]. In the brain, this can lead to decreased methylation, and
therefore decreased production of neurotransmitters. Supporting this are reports of 26%
higher SAH levels in the prefrontal cortex of Alzheimer’s disease patients compared with
normal

controls

and

increased

inhibition

of

catechol-O-mehtyltransferase

and

phenylethanolamine N-methyltransferase (two methyltransferases related to catecholamine
methylation) with increasing brain SAH levels [229]. Lowered activity of these
methyltransferases was also associated with poorer cognitive function, a lower age of onset
and increased severity in markers of neurodegeneration. Furthermore, low concentrations of a
marker of serotonin in the central nervous system (5-hydroxyindole acetic acid in
cerebrospinal fluid, CSF) have been observed in folate-deficient patients with
neuropsychiatric illnesses [230], epilepsy [231] and depression [232], and there is evidence
that administration of intravenous pyridoxine hydrochloride increases synthesis rate of the
neurotransmitter serotonin in the brain of the Rhesus monkey [233]. Further, 5-hydroxyindole
acetic acid and other CSF markers of dopamine turnover (homovanillic acid) and
noradrenaline (3-methoxy-4-hydroyphenylglycol) were reduced in a sub-group of depressed
patients with high plasma total homocysteine [234]. The patients with elevated homocysteine
also presented lowered CSF SAM and lowered serum, red cell and CSF folate but not serum
vitamin B 12 compared with other depressed patients, healthy and neurological control groups.
Folate may also be directly involved in the regulation of neurotransmitter metabolism.
The direct mechanism by which this would occur is still not fully known; however it has been
postulated that tetrahydrobiopterin (BH4) metabolism, a cofactor for the synthesis of
monoamine neurotransmitters which has some structural similarities to folate, could be
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involved [211]. Folate may play a role in the regeneration of BH4 after oxidation, and the
enzymes of folate metabolism, MTHFR and dihydrofolate reductase (DHFR), have been
suggested to be involved in BH4 metabolism. This is supported by reports of correlations
between lower red cell folate, CSF monoamine metabolites and CSF BH4 in depressed
patients [232].
Neurotoxic effects
Homocysteine has been shown to be neurotoxic, leading to DNA damage and
apoptosis [235]. In the nervous system, elevated homocysteine promotes excitotoxicity
through stimulation of NMDA receptors, and induce neuronal DNA damage, triggering
apoptosis and effects on synaptic and glial function [236, 237]. The associated methyl donor
deficiency impacts on DNA repair, causing uracil misincorporation and leading to DNA
strand breakage [238]. DNA damage then activates poly-(ADP-ribose) polymerase (PARP)
leading to cell-cycle arrest or apoptosis through ATP depletion and activation of tumour
suppressor protein (p. 53 [237]). These effects of B vitamin deficiency and/or elevated
homocysteine on DNA repair through DNA nucleotide misincorporation appear to be not
only important in development but also in post-mitotic neurons in the adult [237].
Homocysteine induces apoptosis in rat hippocampal neurons in cell culture, with DNA-strand
breakage, activation of PARP and NAD depletion observed [235]. This precedes
mitochondrial dysfunction, oxidative stress and caspase activation. The authors therefore
proposed a possible endangering effect [235], where elevated homocysteine may sensitize
neurons to the oxidative stress and excitotoxicity already observed in neurodegenerative
disorders [239, 240]. There is also evidence that homocysteine and/or folate deficiency
induced DNA damage can sensitize rat hippocampal neurons to oxidative damage induced by
amyloid B-peptide, specifically through reduced repair of amyloid B-induced oxidative
modification of DNA bases [238].
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These effects of elevated homocysteine on neuronal apoptosis could be enhanced
during aging or in neurodegenerative disorders by the presence of oxidative stress and altered
intracellular calcium homeostasis which accompany them [237]. Homocysteine has also been
shown to be neurotoxic to neurons and neuron cells in culture, particularly in the presence of
elevated glycine which would occur in the case of stroke or head trauma [236]. These
findings could partially explain the observed increased mental health risk in certain clinical
populations, including following stroke or traumatic brain injury, and in frail older people
[241-243].
Oxidative stress
B vitamins may exert neuroprotective effects through modulating homocysteineinduced oxidative stress in the brain. Homocysteine is known to induce oxidative stress
through activation of glutamate receptors and consequent reactive species generation, or by
autoxidation to homocysteine and other disulphides releasing O 2 and H 2 O 2 [244-247].
Studies in animals and humans suggest a role of hyperhomocysteinemia in oxidative
stress associated with poor mental health and also a role for B vitamins in protecting against
these effects. Chronic hyperhomocysteinemia is associated with markers of oxidative damage
and increased DNA damage in the parietal cortex and blood of rats. Concurrent
administration of folic acid prevented these reported effects [246]. Furthermore, folate
deprivation in neuronal cultures produces neurodegenerative changes characteristic to
Alzheimer’s disease, increased cytostolic calcium, increased ROS and decreased oxidative
buffering capacity, accompanied by an increase in homocysteine [245]. Children with autism
have been shown to have a metabolic profile consistent with impaired methylation status and
increased oxidative stress, including lower plasma methionine, SAM, homocysteine,
cystathionine, cysteine and total glutathionine and higher plasma SAH, adenosine and
oxidised glutathionine compared with healthy controls [248]. After supplementation with
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folic acid, betaine and methylcobalamin (vitamin B 12 ), aspects of this abnormal metabolic
profile (methionine, SAM, SAH, adenosine, homocysteine, oxidised glutathionine, cysteine,
total glutathionine) were improved and some reflected the normal levels displayed in the
healthy control children. However, changes in speech and cognition were not assessed,
although some clinical improvements in these were observed by the attending physician.
Although homocysteine can be remethylated into methionine in the presence of folate
and vitamin B 12 , homocysteine can also be converted into cystathionine by the enzyme
cystathionine-β-sythase (CBS) and then to cysteine by γ-cystathionase (Figure 6). This
pathway results in increased levels of the antioxidant glutathione, a possible compensatory
mechanism which counteracts the potential oxidative effects by homocysteine in normal
function [237]. Elevated homocysteine and decreased glutathione have been implicated in
Alzheimer’s disease and Parkinson’s disease [239, 249], which could point towards a
disruption of the transsulfuration pathway as a possible underlying factor in neuropsychiatric
diseases. This effect could be further enhanced by elevated homocysteine induced by vitamin
B 6 , folate and/or vitamin B 12 deficiency. A previous set-back to this theory was that although
production of glutathione from homocysteine-derived cysteine occurs most frequently in the
liver, this pathway was thought be incomplete in the brain for some time [237]. However, this
previously-held belief that conversion of cystathionine to cysteine did not occur in the brain
has been challenged by work in human brain cells and slices which showed an intact and
functional transsulfuration pathway [250]. From this point, given the dependence of sulfur
metabolism on the interaction between gene regulation and B vitamins [251], further
investigations into the neuroprotective effects of vitamin B 6 , folate and vitamin B 12 through
redox homeostasis are important.
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B vitamins, epigenetics and inheritance of psychiatric disorders
In addition to the effects of B vitamin deficiency due to decreased intake during
adulthood and/or decreased absorption in later life on mental health risk discussed above,
there is also some evidence that deficiency

before or during development could be

implicated in mental health in later years and subsequent generations. Poor mental health is
generally thought to have at least some heritable factor. However, there has been a move
towards a focus on low birth weight and “programming” factors through epigenetics, or a
change in gene expression not through alteration in actual DNA sequence but rather DNA
methylation or chromatin structure [252, 253]. Nutrient deficiency at a specific time in fetal
development could have long-lasting effects through tissues, organs and systems including
the central nervous system, in later life. There also is growing evidence that epigenetic
alterations can be transferred to subsequent generations, which may explain the apparent
heritability of complex psychiatric disorders despite the failure to identify candidate genes
[254].
Interestingly, there was a 2-fold increased incidence of schizophrenia [255], and
increased incidence of major affective disorders (unipolar and bipolar) [256] and addictive
disorder especially in men [257] in the Dutch offspring cohort with gestation during the
1944-45 Dutch hunger winter. Although diets during the famine were deficient in many
macro- and micronutrients, a 2.5 fold increased incidence of neural tube defects has been
observed in the cohort, indicating possible folate deficiency in mothers at the time and a
possible epigenetic effect of nutritional deficiency in this cohort [253]. The timing of the
nutritional insult appears to influence risk, with increased schizophrenia and addiction
reported in offspring exposed to the Dutch hunger winter in the first trimester [255, 257],
whilst increased affective disorders were reported in offspring exposed during the second and
third trimesters [256]. The authors proposed that neurodevelopmental events that occur at late
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gestation, including migration of neurons from ventricular zone to the neocortex and neuronal
differentiation [258], could be affected by an insult at this time resulting in disrupted
migration or impaired synaptic connections. There is also evidence to suggest people with
affective disorder and schizophrenia have problems with neuronal structure and synaptic
connections which could be neurodevelopmental in origin [259-261].
These proposed effects on development and function through gene expression could
be implemented through gene-silencing via DNA methylation or gene activation through
methylation of suppressor genes [253]. Folate, vitamin B 6 and vitamin B 12 are all directly or
indirectly involved in one-carbon metabolism and DNA methylation through production of
SAM, a donor in over 80 methylation reactions. Animal models of schizophrenia [262, 263]
have pointed towards hypermethylation of the reelin gene promoter and down-regulation of
reelin and GAD 67 expression, which produces two proteins involved in neuronal migration,
axonal branching, synaptogenesis and cell signalling (reelin) and synthesis of the
neurotransmitter gamma-aminobutyric acid (GAD 67 ) [253]. Human post-mortem studies in
schizophrenia and bipolar disorder have pointed towards the reelin and GAD67 as areas of
interest [264, 265], and reduced reelin mRNA has been observed in autism [266]. Other
candidates for alterations in gene expression leading to schizophrenia include the SOX-10
gene, which codes for an oligodendrocyte-specific transcription factor [267].
Homocysteine, B vitamins and mental health problems
Whilst early clinical observations indicated that frank deficiencies in B vitamins were
associated with cognitive deficit or dementia, it is only since the 1990s that deficiencies in the
“low-normal” range have been considered for a role in dementia [268]. Since then, crosssectional and prospective studies have reported associations between lowered B vitamins
and/or elevated homocysteine in plasma or CSF and increased cognitive decline or dementia
risk (see Smith [268] for review). Evidence from randomised controlled trials for a positive
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effect of homocysteine-lowering B vitamin supplementation on cognitive decline is limited to
date [269]. However, there is evidence of a possible treatment effect at earlier stages of
cognitive decline. A recent trial of older people with mild cognitive impairment, an early risk
factor for dementia, found supplementation with high-dose folic acid, vitamin B 12 and
vitamin B 6 for 24 months was associated with a slowing cognitive decline compared with
placebo, particularly in those with elevated homocysteine [270]. These clinical benefits were
accompanied by a slower rate of brain atrophy in the treatment group as assessed by MRI
[271].
A study conducted in acutely ill hospitalised older patients using a mixed nutrient
supplement containing B vitamins (B 2 , B 6 , B 12 and folate) for 6 weeks found improved
vitamin status and decreased self-rated depressive symptoms in the treatment group
compared with placebo after 6 months but no effect on cognitive function [272]. Plasma total
homocysteine was assessed in a sub sample at baseline and 6 weeks, and mean plasma total
homocysteine was lowered by 22% in the treatment group compared with placebo. Those
with plasma total homocysteine levels in the lowest quartile (≤10µmol/l) after the treatment
period had lower depression scores compared with the highest quartile (≥16.1µmol/l) [273].
It should be noted that older patients which this study excluded due to severe illness,
dementia or living in institutional care are perhaps even more likely to be undernourished and
therefore deficient in B vitamins, and therefore more likely to benefit from supplementation.
Furthermore, as depression is a risk factor for cognitive decline in this group [274, 275], the
effect of B vitamin supplementation on mental well-being in older people should be explored
further.
Cross-sectional research to date has shown some associations between lowered B 6 ,
folate and B 12 and/or elevated homocysteine and increased depression [269].

Recently

published research has shown an association between increased dietary folate intake and
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reduced incidence of depression in young women [276]. Associations between increased
depressive symptoms and lower serum folate levels, but not vitamin B 12 were recently
observed in 2524 adults aged 20-85 years [277]. Vitamin B 12 intakes were not significantly
associated with behaviour scores in a sample of 709 Australian adolescents aged 17 years,
which the authors suggested could be because the mean intake of the sample was above the
recommended dietary intake and/or due to the generally superior absorption of vitamin B 12 in
this younger population compared with older adults. However, lower intakes of vitamins B 1 ,
B 2 , B 3 , B 5 , B 6 and folate were associated with higher externalising (aggressive/delinquent)
behaviour and reduced intake of vitamin B 6 and folate were associated with higher
internalising (withdrawn/depressed) behaviour in this group [278]. There is also a small but
growing body of evidence showing of a beneficial treatment effect of B vitamin
supplementation on depression [269]. In addition, results of randomised controlled trials
investigating folate supplementation as an adjuvant to standard psychotropic medication have
been promising, perhaps due to folate-induced restoration of neurotransmitter function (see
Bottiglieri et al [211]). Considering the links between folate, vitamin B 12 and vitamin B 6 in
metabolism and their role in lowering homocysteine levels, further clinical trials across
mental health should combine the three B vitamins as a more effective method of correcting
deficiency, lowering of homocysteine levels and impacting on clinical outcomes.

DISCUSSION
We have presented multidimensional support for a pivotal role of some key nutrients
and plant-derived phytochemicals from a healthy whole food diet in optimal brain function,
with important implications for cognitive function and mental health. There is a relatively
small body of interventions investigating nutritional supplements, with more research
required. Trials investigating effects of nutritional supplements on mental health assist in
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strengthening the evidence base, but do have their limitations. There is evidence that
combinations of nutrients work together and yet a dearth of research investigating synergistic
properties of nutrients at biochemical, physiological or psychological levels. It is noteworthy,
for instance, that improvements in neuropsychological performance and growth were greater
in Chinese children following supplementation with zinc plus micronutrients than with zinc
or micronutrients alone [279]. It has been argued that psychiatric illness requires broad
spectrum micronutrients due, for instance, to their multiple roles in neurotransmitter synthesis
– although research in this area is lacking [280].
Furthermore, there is a paucity of dietary interventions that focus on mental health
and wellbeing. As highlighted by Jacques and Tucker [281], ‘we don’t eat nutrients, we eat
foods’ (p. 1). Not only do we eat foods in certain patterns, but it is likely that nutrients are
more effective in the complex matrix of a healthy diet, attenuating oxidative and
inflammatory pathways while amplifying a wide range of protective pathways. To assist in
addressing the global crisis around chronic illness, poor mental health, and degenerative
diseases with our aging population, considerable focus is required on research to unravel
synergistic properties of nutrients and investigate benefits of Mediterranean-style whole food
diets for mental as well as cardiometabolic health.
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